Michal Bar‐Natan

TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients

Rafael Bejar, Allegra M. Lord, Kristen E. Stevenson et al. · Blood · 2014 · 556 citations · Full text

Medicine, Genetics, Molecular Genetics +12

Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia

Akinori Yoda, Yuka Yoda, Sabina Chiaretti et al. · Proceedings of the National Academy of Sciences · 2009 · 340 citations · Full text

Life Sciences, Molecular Biology, Oncology +14

The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors

Erik A. Nelson, Sarah R. Walker, Ellen Weisberg et al. · Blood · 2011 · 269 citations · Full text

Medicine, Oncology, Pharmacology +9

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups

Detlef Haase, Kristen E. Stevenson, Donna Neuberg et al. · Leukemia · 2019 · 259 citations · Full text

Life Sciences, Genetics, Hematology +17

Gene expression–based discovery of atovaquone as a STAT3 inhibitor and anticancer agent

Michael Xiang, Haesook Kim, Vincent T. Ho et al. · Blood · 2016 · 113 citations · Full text

Medicine, Oncology, Pharmacology +9